A Phase I Study of RGT-264 in Subjects With Advanced Solid Tumors

Summary

This is a Phase 1 dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of RGT-264 as monotherapy in subjects with advanced solid tumors.

Timeline

Start

2023-02-15

Primary completion

2024-02-20

Completion

2024-02-20

Outcome

Outcome not reported

Stopped: “Due to the change in study plan and not due to safety reasons”

Drugs

Indications